Unauthorized

• Anthropic's Mythos AI model, which the company deemed too dangerous for public release, has reportedly been accessed by an unauthorized third party in a significant security breach. • The incident has raised global concerns about AI safety and the security protocols surrounding advanced AI systems, particularly models flagged as high-risk by their developers. • The breach underscores ongoing tensions between AI safety considerations and cybersecurity vulnerabilities in the management of cutting-edge language models.

• Anthropic is investigating unauthorized access to its Mythos AI tool, a critical cybersecurity system, after reports revealed that an unauthorized group breached the platform via a vendor vulnerability. • The incident raises fresh concerns about security gaps within advanced AI systems and amplifies questions about the trustworthiness of AI tools handling sensitive security functions. • The breach exemplifies broader risks in the interconnected tech ecosystem, where vendor compromises can cascade into exposures of high-value AI infrastructure.

• The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions. • Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment. • The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.